CompanyGraph
BioArctic AB
BIOA.B · Nasdaq Stockholm · Sweden
Price data from its BIOABs listing on CBOE
bioarctic.seFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.11B, above the global median of $1.15B
- PositionOperating margin is 45.9%, higher than 95% of its Biotechnology peers (median -34.2%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.62%
Annual Rate
SEK 2.00Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
29.50BSEK3.11B · vs all stocks (USD)
Trailing P/E
138.58xvs Biotechnology peers
Revenue (TTM)
1.15BSEK120.86M · vs all stocks (USD)
Profit Margin
18.59%vs Biotechnology peers
Beta
-0.6810xvs all stocks
52-Week Change
39.14%vs all stocks
Forward Annual Dividend Yield
0.62%vs all stocks
Market Capitalization
29.50BSEK3.11B · vs all stocks (USD)
Enterprise Value
26.63BSEK2.81B · vs all stocks (USD)
Trailing P/E
138.58xvs Biotechnology peers
Forward P/E
114.21xvs Biotechnology peers
PEG Ratio
-1.75xvs Biotechnology peers
Price to Sales (TTM)
25.62xvs Biotechnology peers
Price to Book (MRQ)
13.37xvs Biotechnology peers
Enterprise to Revenue
23.21xvs Biotechnology peers
Enterprise to EBITDA
20.97xvs Biotechnology peers
Gross Margin
95.53%vs Biotechnology peers
Profit Margin
18.59%vs Biotechnology peers
Operating Margin
45.92%vs Biotechnology peers
Return on Assets (TTM)
12.88%vs Biotechnology peers
Return on Equity (TTM)
10.32%vs Biotechnology peers
Revenue (TTM)
1.15BSEK120.86M · vs all stocks (USD)
Revenue per Share (TTM)
12.95SEKUpdated Aug 21, 2026Quarterly Revenue Growth
-66.10%vs Biotechnology peers
Gross Profit (TTM)
1.08BSEK113.76M · vs all stocks (USD)
EBITDA (TTM)
1.27BSEK133.76M · vs all stocks (USD)
Net Income (TTM)
213.24MSEK22.47M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-79.20%vs Biotechnology peers
Operating Cash Flow (TTM)
1.25BSEK132.04M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.26BSEK132.62M · vs all stocks (USD)
Forward Annual Dividend Rate
2.00SEKUpdated Aug 21, 2026Forward Annual Dividend Yield
0.62%vs all stocks
Trailing Annual Dividend Rate
2.00SEKUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.62%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.00BSEKFY2025 · Dec 31, 2025Cost of Goods Sold
59.22MSEKFY2025 · Dec 31, 2025Gross Profit
1.94BSEKFY2025 · Dec 31, 2025Operating Income
1.26BSEK132.63M · vs all stocks (USD)
Pre-tax Income
1.26BSEKFY2025 · Dec 31, 2025Income Tax Expense
233.26MSEKFY2025 · Dec 31, 2025Net Income
1.02BSEKFY2025 · Dec 31, 2025EBIT
1.29BSEKFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.29BSEKFY2025 · Dec 31, 2025Research & Development
376.92MSEKFY2025 · Dec 31, 2025Selling, General & Administrative
194.83MSEKFY2025 · Dec 31, 2025Other Operating Expenses
125.54MSEKFY2025 · Dec 31, 2025Non-operating Interest Income
34.68MSEKFY2025 · Dec 31, 2025Non-operating Interest Expense
37.90MSEKFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00SEKFY2025 · Dec 31, 2025Operating Cash Flow
1.43BSEKFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.04BSEKFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.26BSEKFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-64.77MSEKFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
238.99MSEKFY2025 · Dec 31, 2025Shares Outstanding
88.72MSharesUpdated Aug 21, 2026Float Shares
54.40MSharesUpdated Aug 21, 2026% Held by Insiders
42.68%vs all stocks
% Held by Institutions
34.41%vs all stocks
Total Cash (MRQ)
2.03BSEK214.37M · vs all stocks (USD)
Total Cash per Share (MRQ)
22.93SEKUpdated Aug 21, 2026Total Debt (MRQ)
40.74MSEK4.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0185xvs Biotechnology peers
Current Ratio (MRQ)
6.54xvs Biotechnology peers
Book Value per Share (MRQ)
24.77SEKUpdated Aug 21, 2026Total Assets
2.58BSEK271.33M · vs all stocks (USD)
Total Current Assets
2.49BSEKFY2025 · Dec 31, 2025Total Liabilities
608.14MSEKFY2025 · Dec 31, 2025Total Non-current Assets
88.27MSEKFY2025 · Dec 31, 2025Total Non-current Liabilities
87.37MSEKFY2025 · Dec 31, 2025Total Current Liabilities
520.78MSEKFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.04BSEKFY2025 · Dec 31, 2025Other Short-term Investments
1.15BSEKFY2025 · Dec 31, 2025Short-term Debt
15.72MSEKFY2025 · Dec 31, 2025Other Current Liabilities
171.00MSEKFY2025 · Dec 31, 2025Long-term Debt
28.35MSEKFY2025 · Dec 31, 2025Total Shareholders' Equity
1.97BSEK207.25M · vs all stocks (USD)
52-Week Low
235.00SEKUpdated Aug 21, 202652-Week High
364.40SEKUpdated Aug 21, 202652-Week Change
39.14%vs all stocks
Beta
-0.6810xvs all stocks
50-Day MA
313.34SEKUpdated Aug 21, 2026200-Day MA
315.51SEKUpdated Aug 21, 2026Avg 10-Day Volume
136.06KSharesUpdated Aug 21, 2026Avg 30-Day Volume
121.86KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
2.39SEKUpdated Aug 21, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 45.9%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.46Industry median: -0.34Industry P95: 0.41Peers compared: 261
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 25.62Revenue Growth YoY: -0.66
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 5.07
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.11B, above the global median of $1.15BNotable
Market cap (USD): 3,108,107,917.421Global Median: 1,146,734,693.424
Levered free cash flow is $132.62M, above the global median of $16.24MNotable
Levered free cash flow (USD): 132,622,245.581Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Wockhardt Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Keeper Technical Laboratory
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash-Backed Growth ConfigurationROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Sk Biopharmaceuticals Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Shanghai Allist Pharmaceuticals Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsROE, ROA, And Operating ROA ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated